Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ADX-850

Phase 1Small molecule

AADARx Pharmaceuticals, Inc.

ADX-850 is one of 34 small molecule programs targeting Hypertension. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

33

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertensionActive, not recruiting

HypertensionPhase 1

Active, not recruiting

Competition

Competitive Landscape

157 competitors in Hypertension

#DrugCompanyPhaseTrials

Baxfendy

Foundayo

Nitrostat

VViatris Specialty LLC

Alka-Seltzer

HCP1803-3

Hanmi Pharmaceutical Company Limited

SGLT2

PProf. Dr. med. Ingo Eitel

Avastin

Winrevair

Alphagan

Deltavit

HHyundai Pharmaceutical Co., LTD.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Hypertension

NCT06205628

Clinical

Trials by Indication[1]

Hypertension1 trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ADX-850 in Participants With Hypertension

Active, not recruiting·AADARx Pharmaceuticals, Inc.·Phase 1·NCT06205628·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ADX-850. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ADX-850 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ADX-850. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ADARx Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AADARx Pharmaceuticals, Inc.

Related News